keynote-361 and -045: pembrolizumab monotherapy in urothelial carcinoma
Published 1 year ago • 100 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
5:04
keynote-361: ctdna as a biomarker in advanced urothelial carcinoma
-
3:20
updates on the danube, keynote-361 and javelin studies
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
1:38
keynote 361: pembrolizumab compared to gemcarbo - bladder cancer video library
-
1:54
two-year follow-up results from keynote-045 study in urothelial carcinoma
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
0:30
enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
0:57
dr. petrylak on the keynote-045 trial for urothelial carcinoma
-
0:51
impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
-
1:19
dr. bellmunt shares keynote-045 data for pembrolizumab versus chemotherapy in bladder cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
2:43
pembrolizumab: defining standards of care in urothelial cancer
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
5:26
updates in 1l urothelial cancer from esmo 2020
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer